Arabic Arabic English English French French German German
dark

Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio from DeuteRx, LLC

Salarius Pharmaceuticals, Inc. today announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Yorkshire and Humber AHSN showcase innovations to senior NHS figures

Next Post

Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)

Related Posts
Total
0
Share